1. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting;Richardson;Blood Cancer J,2018
2. Millennium Pharmaceuticals Inc. NINLARO® (ixazomib) capsules, for oral use. United States Prescribing Information; revised: April 2022. Accessed: June 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208462s012s013lbl.pdf.
3. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma;Moreau;N Engl J Med,2016
4. Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma;Terpos;Ann Hematol,2020
5. Takeda Pharma A/S. NINLARO: EPAR product information. summary of product characteristics; last updated: 05 September 2023. Accessed: June 2023. Available at: https://www.ema.europa.eu/en/documents/product-information/ninlaro-epar-product-information_en.pdf.